Nature Communications (Oct 2024)
The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma
- Guozhong Jiang,
- Zhizhong Wang,
- Zhenguo Cheng,
- Weiwei Wang,
- Shuangshuang Lu,
- Zifang Zhang,
- Chinedu A. Anene,
- Faraz Khan,
- Yue Chen,
- Emma Bailey,
- Huisha Xu,
- Yunshu Dong,
- Peinan Chen,
- Zhongxian Zhang,
- Dongling Gao,
- Zhimin Wang,
- Jinxin Miao,
- Xia Xue,
- Pengju Wang,
- Lirong Zhang,
- Rathi Gangeswaran,
- Peng Liu,
- Louisa S. Chard Dunmall,
- Junkuo Li,
- Yongjun Guo,
- Jianzeng Dong,
- Nicholas R. Lemoine,
- Wencai Li,
- Jun Wang,
- Yaohe Wang
Affiliations
- Guozhong Jiang
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University
- Zhizhong Wang
- Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
- Zhenguo Cheng
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University
- Weiwei Wang
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University
- Shuangshuang Lu
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University
- Zifang Zhang
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University
- Chinedu A. Anene
- Centre for Cancer Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London
- Faraz Khan
- Centre for Cancer Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London
- Yue Chen
- Centre for Cancer Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London
- Emma Bailey
- Centre for Cancer Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London
- Huisha Xu
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University
- Yunshu Dong
- CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences
- Peinan Chen
- Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
- Zhongxian Zhang
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University
- Dongling Gao
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University
- Zhimin Wang
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University
- Jinxin Miao
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University
- Xia Xue
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University
- Pengju Wang
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University
- Lirong Zhang
- Department of Pharmacology, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Rathi Gangeswaran
- Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute, Queen Mary University of London
- Peng Liu
- Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute, Queen Mary University of London
- Louisa S. Chard Dunmall
- Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute, Queen Mary University of London
- Junkuo Li
- Department of Molecular Pathology, Anyang Cancer Hospital
- Yongjun Guo
- Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
- Jianzeng Dong
- Department of Cardiology, Centre for Cardiovascular Diseases, The First Affiliated Hospital of Zhengzhou University
- Nicholas R. Lemoine
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University
- Wencai Li
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University
- Jun Wang
- Centre for Cancer Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London
- Yaohe Wang
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Zhengzhou University
- DOI
- https://doi.org/10.1038/s41467-024-53164-x
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 17
Abstract
Abstract Esophageal squamous cell carcinoma (ESCC) is highly heterogeneous. Our understanding of full molecular and immune landscape of ESCC remains limited, hindering the development of personalised therapeutic strategies. To address this, we perform genomic-transcriptomic characterizations and AI-aided histopathological image analysis of 120 Chinese ESCC patients. Here we show that ESCC can be categorized into differentiated, metabolic, immunogenic and stemness subtypes based on bulk and single-cell RNA-seq, each exhibiting specific molecular and histopathological features based on an amalgamated deep-learning model. The stemness subgroup with signature genes, such as WFDC2, SFRP1, LGR6 and VWA2, has the poorest prognosis and is associated with downregulated immune activities, a high frequency of EP300 mutation/activation, functional mutation enrichment in Wnt signalling and the highest level of intratumoural heterogeneity. The immune profiling by transcriptomics and immunohistochemistry reveals ESCC cells overexpress natural killer cell markers XCL1 and CD160 as immune evasion. Strikingly, XCL1 expression also affects the sensitivity of ESCC cells to common chemotherapy drugs. This study opens avenues for ESCC treatment and provides a valuable public resource to better understand ESCC.